Robeco Institutional Asset Management B.V. Sells 21,262 Shares of Jazz Pharmaceuticals PLC $JAZZ

Robeco Institutional Asset Management B.V. trimmed its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 18.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,350 shares of the specialty pharmaceutical company’s stock after selling 21,262 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.15% of Jazz Pharmaceuticals worth $22,307,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp lifted its position in Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after buying an additional 517,514 shares in the last quarter. Bank of America Corp DE increased its position in shares of Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after acquiring an additional 99,656 shares in the last quarter. Boston Trust Walden Corp increased its position in shares of Jazz Pharmaceuticals by 24.1% in the first quarter. Boston Trust Walden Corp now owns 488,661 shares of the specialty pharmaceutical company’s stock worth $92,381,000 after acquiring an additional 94,750 shares in the last quarter. Systematic Financial Management LP raised its stake in shares of Jazz Pharmaceuticals by 2.6% in the 1st quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock valued at $76,965,000 after acquiring an additional 10,237 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at $60,496,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In related news, CEO Renee D. Gala sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total value of $486,060.00. Following the sale, the chief executive officer owned 143,394 shares of the company’s stock, valued at approximately $34,849,043.82. This trade represents a 1.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the transaction, the executive vice president owned 47,671 shares of the company’s stock, valued at $11,485,850.74. This represents a 2.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 100,121 shares of company stock valued at $24,855,802 over the last three months. 4.10% of the stock is owned by company insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $214.00 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.80 and a fifty-two week high of $266.38. The firm has a 50-day simple moving average of $236.11 and a 200 day simple moving average of $232.83. The company has a market cap of $13.89 billion, a PE ratio of 9.29, a P/E/G ratio of 0.22 and a beta of 0.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same quarter last year, the company earned ($8.25) EPS. Jazz Pharmaceuticals’s revenue was up 15.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 21.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on JAZZ. Deutsche Bank Aktiengesellschaft upped their price target on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Piper Sandler raised their price objective on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Stifel Nicolaus set a $275.00 price objective on Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Royal Bank Of Canada reduced their price objective on Jazz Pharmaceuticals from $299.00 to $296.00 and set an “outperform” rating on the stock in a research note on Thursday, October 8th. Finally, Wall Street Zen downgraded Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $290.85.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.